Article
The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
BMC cancer - 20 Mar 2018
Fidler Mary Jo, Fhied Cristina L, Roder Joanna, Basu Sanjib, Sayidine Selina, Fughhi Ibtihaj, Pool Mark, Batus Marta, Bonomi Philip, Borgia Jeffrey A
Abstract excerpt
BACKGROUND: The VeriStrat test is a serum proteomic signature originally discovered in non-responders to second line gefitinib treatment and subsequently used to predict differential benefit from erlotinib versus chemotherapy in previously treated advanced non-small cell lung cancer (NSCLC). Multiple studies highlight the clinical utility of the VeriStrat test, however, the mechanistic connection between...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.